Why Parkinson's Disease is a Target for Stem Cell Therapy
Parkinson's disease (ICD-10: G20) is the second most common neurodegenerative disorder after Alzheimer's, affecting an estimated 10 million people globally. It is characterised by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta — a region of the midbrain responsible for motor control. As dopamine production falls, patients develop the hallmark triad of tremor, muscular rigidity, and bradykinesia (slowed movement), often accompanied by non-motor symptoms including cognitive decline, autonomic dysfunction and sleep disturbances.
Current standard of care — primarily levodopa, dopamine agonists and monoamine oxidase B inhibitors — addresses symptoms but does not slow or reverse underlying neurodegeneration. Deep brain stimulation (DBS) is effective for selected patients but again does not modify disease course. This therapeutic gap makes Parkinson's disease one of the highest-priority targets for regenerative medicine.
iPSC-Derived Dopamine Neuron Replacement
The most direct approach to regenerating lost tissue is to replace the dopaminergic neurons themselves. Induced pluripotent stem cells (iPSCs) — adult cells reprogrammed to an embryonic-like pluripotent state — can be directed to differentiate into authentic dopaminergic neurons suitable for transplantation.
The pivotal 2018 study published in Nature (doi:10.1038/nature25830) demonstrated that human iPSC-derived dopaminergic neurons, transplanted into a primate model of Parkinson's disease, survived, integrated into the host circuitry, and produced measurable improvements in motor function over a 24-month observation period. Critically, the study also showed that autologous iPSCs (derived from the patient's own cells) were tolerated without immunosuppression — a significant safety advantage.
By 2022, GMP-grade (Good Manufacturing Practice) iPSC production protocols had reached clinical readiness. A Cell Stem Cell paper that year described standardised processes for producing transplant-ready dopaminergic neuron populations, moving iPSC therapy closer to clinical application outside of research settings.
Mesenchymal Stem Cell Therapy: Neuroprotection and Anti-Inflammation
MSCs (mesenchymal stem cells) operate through a different mechanism — rather than replacing lost neurons directly, they modulate the inflammatory and oxidative environment in which neurodegeneration occurs. MSCs secrete neurotrophic factors (BDNF, GDNF, NGF) that support neuron survival, reduce microglial-driven neuroinflammation, and may protect remaining dopaminergic neurons from further loss.
A 2020 systematic review in NPJ Parkinson's Disease analysed published MSC studies and found consistent evidence of neuroprotective effects in preclinical models, with early human studies reporting improvement in both motor and non-motor symptoms. MSC therapy is also associated with a more established safety profile than iPSC-based approaches, given the absence of pluripotent cells in the final product.
Target150 uses MSCs sourced from placenta, cord tissue and adipose tissue — all rich sources of high-potency mesenchymal cells processed in the clinic's ISO Class 7 cleanroom laboratory.
Clinical Evidence Summary
| Study / Intervention | Journal | Year | Key Finding |
|---|---|---|---|
| Human iPSC → dopaminergic neurons, primate model | Nature | 2018 | Motor function improvement; autologous cells tolerated without immunosuppression |
| MSC therapy systematic review (Parkinson's) | NPJ Parkinson's Disease | 2020 | Consistent neuroprotective effects; early human studies show motor + non-motor improvement |
| GMP-grade iPSC dopamine neuron production | Cell Stem Cell | 2022 | Clinical-grade production protocols validated; standardised potency and safety testing |
Target150's Approach to Parkinson's Disease
Target150 offers MSC-based stem cell therapy for Parkinson's patients as part of its medical regenerative medicine programme. All patients undergo a comprehensive bio-longevity screening — including hormone panels, NK cell count, and micronutrient analysis — before a personalised treatment protocol is designed.
MSCs can be administered via multiple routes: intravenous infusion, direct injection into cerebrospinal fluid (intrathecal), or a combination approach. The optimal protocol depends on disease stage, patient health status, and clinical assessment by Target150's medical team.
Patients travel to the clinic at 622 Emporium Tower, Sukhumvit 24, Bangkok from Australia, the UK, the US and Europe. Thailand's regulatory environment is favourable to regenerative medicine, and costs are substantially lower than equivalent private programmes in Western countries.
Limitations and What Patients Should Know
- Stem cell therapy for Parkinson's is investigational. It is not an FDA- or EMA-approved first-line treatment. Results vary between individuals.
- Disease stage matters. Patients with earlier-stage Parkinson's who retain more surviving dopaminergic neurons are generally better candidates for neuroprotective MSC approaches than late-stage patients.
- Combination therapy may be most effective. Stem cell therapy is best considered as complementary to, not a replacement for, established neurological care and medication management.
- Follow-up is essential. Motor function assessments at 3, 6 and 12 months provide evidence of response and guide protocol adjustments.
Frequently Asked Questions
Can stem cell therapy treat Parkinson's disease?
Stem cell therapy — particularly iPSC-derived dopamine neuron replacement — has shown promising results in primate models and early human trials. The 2018 Nature study confirmed that human iPSC-derived cells can regenerate dopamine-producing neurons in the substantia nigra. MSC therapy has also demonstrated neuroprotective effects. Results in individual patients vary, and the therapy remains investigational rather than an established standard of care.
What type of stem cells are used for Parkinson's disease?
Two main types: (1) iPSCs differentiated into dopaminergic neurons to replace cells lost in the substantia nigra; and (2) MSCs which offer neuroprotective and anti-inflammatory effects. Target150 uses MSC therapy sourced from placenta, cord tissue and adipose tissue.
Where can I receive stem cell therapy for Parkinson's disease?
Target150 in Bangkok, Thailand offers MSC-based stem cell therapy for Parkinson's disease as part of its medical regenerative medicine programme. Contact the clinic for a consultation.
What are the risks of stem cell therapy for Parkinson's disease?
Potential risks include immune rejection, tumour formation (particularly with iPSC-derived cells), infection, and graft-induced dyskinesia. Not all patients respond to treatment, and outcomes vary. All treatments should be discussed with a qualified neurologist and regenerative medicine specialist.